Get the Stockscreener App
6.09
5.58%
-0.36
After Hours:
6.00
-0.09
-1.48%
C 4 Therapeutics Inc stock is traded at $6.09, with a volume of 2.81M.
It is down -5.58% in the last 24 hours and up +13.20% over the past month.
C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.
See More
Previous Close:
$6.45
Open:
$6.2
24h Volume:
2.81M
Relative Volume:
2.99
Market Cap:
$429.89M
Revenue:
$20.76M
Net Income/Loss:
$-132.49M
P/E Ratio:
-2.1368
EPS:
-2.85
Net Cash Flow:
$-108.55M
1W Performance:
+3.22%
1M Performance:
+13.20%
6M Performance:
-9.64%
1Y Performance:
+290.38%
1-Day Range:
$5.84
$6.3695
1-Week Range:
$5.2219
$6.52
52-Week Range:
$1.06
$11.88
C 4 Therapeutics Inc Stock (CCCC) Company Profile
Name
C 4 Therapeutics Inc
Sector
Industry
Phone
(617) 231-0700
Address
490 ARSENAL WAY, WATERTOWN
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-23 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-24-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-04-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Underweight |
| Apr-28-22 | Initiated | Credit Suisse | Underperform |
| Apr-11-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-10-22 | Initiated | JP Morgan | Overweight |
| Feb-11-22 | Resumed | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Nov-23-21 | Initiated | BofA Securities | Buy |
| Oct-14-21 | Initiated | SVB Leerink | Mkt Perform |
| Sep-30-21 | Initiated | Stifel | Hold |
| Jun-04-21 | Initiated | H.C. Wainwright | Buy |
| Mar-31-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Oct-27-20 | Initiated | BMO Capital Markets | Outperform |
| Oct-27-20 | Initiated | Jefferies | Buy |
View All
C 4 Therapeutics Inc Stock (CCCC) Latest News
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin's Lymphoma at the American Society of Hematology (ASH) Annual Meeting - The Manila Times
C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin's Lymphoma At the American Society of Hematology Annual Meeting - Marketscreener.com
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Marketscreener.com
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Kilgore News Herald
C4 Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics Advances in Protein Degradation Therapy - TipRanks
C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Tops Revenue Estimates - MSN
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - The Manila Times
C4 Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
We're Hopeful That C4 Therapeutics (NASDAQ:CCCC) Will Use Its Cash Wisely - Yahoo Finance
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
C4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Update - MarketBeat
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Citizentribune
C4 Therapeutics appoints Paige Mahaney as new CSO - Investing.com India
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics appoints Paige Mahaney as new CSO By Investing.com - Investing.com Canada
C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer - citybiz
C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief - GlobeNewswire
C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D. - StockTitan
How should investors view C4 Therapeutics Inc (CCCC)? - US Post News
C4 Therapeutics Inc: Navigating Market Fluctuations with a 407.72M Market Cap - The InvestChronicle
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire
Financial Metrics Exploration: Understanding C4 Therapeutics Inc (CCCC) Through Ratios - The Dwinnex
C4 Therapeutics amends incentive plan, barring repricing without shareholder nod - Investing.com
C4 Therapeutics amends incentive plan, barring repricing without shareholder nod By Investing.com - Investing.com South Africa
Squarepoint Ops LLC Has $264,000 Holdings in C4 Therapeutics, Inc. (NASDAQ:CCCC) - Defense World
Cubist Systematic Strategies LLC Has $2.59 Million Stake in C4 Therapeutics, Inc. (NASDAQ:CCCC) - MarketBeat
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit - The Manila Times
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) - Yahoo Finance
Renaissance Technologies LLC Has $1.09 Million Stake in C4 Therapeutics, Inc. (NASDAQ:CCCC) - MarketBeat
C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Average Rating of "Hold" by Brokerages - MarketBeat
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewswire
C 4 Therapeutics Inc Stock (CCCC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):